Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H(1)-antihistamines. Omalizumab is a humanized monoclonal anti-IgE antibody that binds with free IgE antibodies and reduces the circulating levels of fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Godse, Kiran, Rajagopalan, Murlidhar, Girdhar, Mukesh, Kandhari, Sanjiv, Shah, Bela, Chhajed, Prashant N., Tahiliani, Sushil, Shankar, D. S. Krupa, Somani, Vijay, Zawar, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763587/
https://www.ncbi.nlm.nih.gov/pubmed/26955580
http://dx.doi.org/10.4103/2229-5178.174314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763587/
https://www.ncbi.nlm.nih.gov/pubmed/26955580
http://dx.doi.org/10.4103/2229-5178.174314

Ejemplares similares